|Publication number||US3914413 A|
|Publication date||Oct 21, 1975|
|Filing date||Jul 9, 1973|
|Priority date||Feb 10, 1971|
|Publication number||US 3914413 A, US 3914413A, US-A-3914413, US3914413 A, US3914413A|
|Inventors||Leslie L Balassa|
|Original Assignee||Leslie L Balassa|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (4), Referenced by (65), Classifications (11), Legal Events (1)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent 1 1111 3,914,413
Balassa 1 *Oct. 21, 1975 PROCESS FoR FACILITATING WOUND  Field Of Search 424/180, 28, 95
HEALING WITH N-ACETYLATED PARTIALLY DEPOLYMERIZED cIIITIN  References Cited MATERIALS UNITED STATES PATENTS  Inventor: Leslie Balassa, Tomahawk Lake 2 040 879 5/1936 Rigby 260/54 Bloommg Grove, 10914 2,795,579 6/1957 Doczi 260/211 3,232,836 2/1966 Carlozzi et al..... 424/180 1 Nome The porno of the term of thls 3,257,275 6 1966 Weisberg 61. a1. 424/330 patent subsequent to Jan. 4, 1989,
has been disclaimed.
Primary ExaminerStanley J. Friedman Filed: y 9, 1973 Assistant Examiner-Daren M. Stephens 1 APPL 377,505 Attorney, Agent, or FirmDarby & Darby Related US. Application Data AB RA T  Continuation of Ser. No. 114,350, Feb. 10, 1971,  ST C abandoned, which is a division of Ser. No. 704,538, Wound healing compositions and the process of heal- Feb. 12, 1968, and a continuation-in-part of Ser. No. ing wounds with such compositions are described, the 619,007, 27, 19671 abandonedcompositions containing chitin, partially depolymerized chitin or a chitin derivative.  US. Cl. 424/180; 424/28; 424/95  Int. Cl. A61K 31/70; A61K 9/70;
A61K 35/12 11 Claims, No Drawings PROCESS FOR FACILITATING WOUND HEALING WITH N-ACETYLATED PARTIALLY DEPOLYMERIZED CHITIN MATERIALS healing of wounds. Patients suffering from diabetes or undergoing extensive cortisone treatment show extremely slow rates of healing of any wounds which they receive. Thus, surgery on such patients involves additional risks not present with other patients. Moreover, rapid healing of wounds is particularly desired for patients in tropical countries where the risk of infection is high. Rapid healing is also desired in the case of soldiers who have been wounded in a battle zone and cannot easily and quickly be removed therefrom. Acceleration of wound healing is highly desirable in the case of patients who cannot readily be immobilized, such as farm animals.
In evaluating the utility of a material to promote wound healing, a reproducible test is necessary to give comparative data. Such a test method has been described by Prudden et al in: The Acceleration of Wound Healing with Cartilage, Surgery, Gynecology and Obstetrics, 105:283 (1957). In this method, rats are tested in pairs, each pair receiving an identical surgical incision, only the one rat of the pair receiving a measured dose of the material whose wound healing properties is to be determined. The pair is then kept in the same cage and the tensile strength of the wounds in the two rats is determined in millimeters of mercury. The difference in the tensile strengths between the treated rat and the control rat is expressed as the percentage improvement obtained. Considering biological variance it is believed that only differences of about or more are significant.
There have been several recent developments reported concerning materials which promote wound healing. In this connection US. Pat. No. 3,232,836 describes the parenteral administration of N- acetylglucosamine as a wound healing material. Utilizing the test method of Prudden et al referred to in the preceding paragraph, N-acetylglucosamine showed improvement in tensile strength of only about 10% whereas Prudden and his co-workers have reported significantly larger increases in wound healing by the use of cartilage preparations from various. animals. Depending on the age and species of animal and the fineness of the cartilage powder, improvements ranging from to in wound healing tensile strength have been reported by Prudden.
Now it has been discovered that finely divided chitin, partially depolymerized chitin, and chitin derivatives possess the ability to promote the healing of wounds.
Accordingly, one aspect of the present invention relates to novel methods of promoting and assisting the healing of wounds as, for example, damaged mammalian tissue, open ulcers, etc., and to compositions therefor.
Another aspect of the invention relates to significant improvements in wound healing strength achieved by the administration of finely divided chitin, partially depolymerized chitin or chitin derivatives to a patient.
An additional aspect of the present invention is concerned with articles of manufacture such as surgical bandages, surgical sutures, etc., containing the wound healing materials of the present invention.
These and other aspects of the present invention will be apparent from the following description.
Chitin is a polysaccharide, believed to be poly (N- acetylglucosamine) which forms the cell walls of fungi and the hard shell of insects and crustaceans. As used herein, the term chitin embraces naturally occurring chitin, synthetic chitin, as well as poly (N- acetylglucosamine) and its epimer poly (N- acetylgalactosamine). The partially depolymerized chitin, e.g. chitotriose, chitobiose, is a substance which retains its polymeric nature but has undergone a reduction in molecular weight (i.e., chain length) as a result of (1) enzymatic action such as by a chitinase enzyme (2) chemical treatment such as acid hydrolysis or alkaline treatment, and (3) physical treatment.
The chitin derivatives contemplated are materials such as ethers formed with pharmaceutically acceptable radicals and esters or salts with pharmaceutically acceptable acids. Examples of suitable derivatives include hydroxy lower alkyl chitin such as hydroxyethyl chitin, carboxy alkyl chitin such as carboxymethyl chitin, salts of carboxy lower alkyl chitin such as the zinc salt, lower alkyl chitin such as methyl chitin and ethyl chitin, chitin acetate, chitin nitrate, chitin citrate chitin phosphate, N-acyl derivatives derived from monocarboxylic aliphatic acids such as N-formyl, N-acetyl, N- propionyl, N-caproyl, etc.
It is preferred to use natural chitin as the wound healing accelerator. The naturally occurring chitin is preferably chitin of fungal origin, both by reason of its ready availability and its high degree of effectiveness.
The degree of improvement in wound healing ob-. tained with the chitin materials is at least equal to and in many instances greater than that derived from the cartilage materials of the prior art. The substantial improvement in rate of healing which is obtained from the use of poly(N-acetylglucosamine), i.e., chitin, as compared to monomeric N-acetylglucosamine is particularly surprising. As compared to the greater variability in cartilage depending on the animal, its age and the method of collecting the cartilage, chitin, particularly chitin of fungal origin, is a relatively uniform and easily obtained material.
The compositions of the present invention are applied using the same techniques and processes developed for cartilage, and N-acetylglucosamine. Thus, it is preferred to topically apply finely divided chitin directly to the wound surface. However, tablets, capsules or pellets of chitin may be prepared from mixtures of chitin, partially depolymerized chitin or chitin derivatives with well-known pharmaceutical excipients such as starch, sugar, certain forms of clay, etc. Such tablets, capsules or pellets may be taken orally or implanted near the situs of the wound. Alternatively, a colloidal solution may be prepared from chitin, preferably in isotonic saline, or a water-soluble derivative of chitin may be dissolved preferably in isotonic saline solution, and
the solution administered intramuscularly, parenterally or intravenously.
A powder or solution of chitin or of a chitin derivative may also be used to impregnate a surgical gauze or pad which is applied to the wound. Chitin may also be dissolved as the alkali chitin xanthate, spun into fibers and regenerated as the virtually undegraded polymer in accordance with the procedures described in the prior art by Thor et al. Partially deacetylated chitin filaments and fibers may be prepared in accordance with the procedure described in U.S. Pat. No. 2,040,880. These chitin fibers may then be used as surgical sutures or included in bandages or other support base for surgical dressings either in a woven or nonwoven fabric structure in the manner described in U.S. Pat. No.
3,196,075. Chitin or chitin derivative may also be made up into an ointment or salve. The use of nonactive carriers for the chitin is not preferred as the presence of extraneous matter in a wound frequently tends to interfere with the healing process due to the interposition effect.
As previously stated, where the chitin is to be applied by injection, i.e., either intramuscularly, parenterally or intravenously, it is first necessary to prepare a dispersion or a solution of the material in a pharmaceutically acceptable liquid. Colloidal solutions of chitin may be prepared using the method described by Lingappa and Lockwood in NATURE, 189, page 158 (1961). When administered intravenously it is preferred to administer the compound in isotonic solution such as isotonic saline.
The chitin or chitin derivatives may be used alone, in admixture with each other, with cartilage, or may be co-administered with other therapeutically effective agents such as ascorbic acid, ascorbyl palmitate, pharmaceutically acceptable zinc salts such as zinc oxide, zinc ascorbate, zinc sulfate and zinc stearate; antiseptics such as thimerosal and benzalkonium chloride; local anesthetics such as lidocaine and procaine; antibiotics such as chloramphenicol, sulfanilamide and ampicilline. Combinations of the therapeutically effective agents described above with chitin and/or chitin derivatives may be used.
Suitable sources of chitin are from lobsters, shrimp and other crustacea. To utilize chitin from such sources, it is necessary to reduce the chitin in particle size to less than about 150 microns and preferably less than about 50 microns. Due to the tough and rather fibrous nature of chitin from such sources, this grinding is difficult and expensive. Accordingly, it is preferred to use chitin of fungal origin. The cell walls of fungi are made of chitin. [t has been found that it is not necessary to extract the chitin from the remaining cell material. Thus, if desired, after suitable sterilization as by heat or gas (i.e., ethylene oxide), the entire fungal mat produced by fermentation ofa fungus in a suitable nutrient medium may be ground and used to promote healing of wounds. Preferably, however, the fungal mat is treated to remove the extraneous materials leaving only the chitin skeletons. Purifying the material in this manner eliminates the nonchitinous materials, thus substantially reducing the possibility of an allergic reaction and eliminating any interference with the healing process which might be caused by such materials.
Finely divided chitin or chitin derivatives may be applied topically by blowing a metered amount of the material onto the wound using a hand atomizer. Altnernatively, it may be applied by dusting as from a hand shaker or may be placed together with an inert gas under increased pressure (i.e., above atmospheric pressure) in a pressure vessel. In this latter means of application, termed aerosol application, the finely divided chitin or chitin derivative, optionally with other medicaments as indicated, maybe packaged as a dry aerosol powder as described in Dutch patent application No. 6,415,252, published July 5, 1965 (this patent application is directed to a medicament for bovine mastitis but the method of aerosol packaging described is applicable to powdered medicament having the described particle size) or as an aerosol foam.
In the following examples, the wound healing efficiency of the various chitinous materials is determined by using the method of Prudden et al as described above. In general, at least 10 pairs of rats are used to obtain a meaningful average for each material tested. In each of these examples a powder insufflator is used to apply 2 to 10 mg./cm of wound surface of the material tested.
EXAMPLE 1 Commercial lobster shell chitin is ground to a fine powder in a laboratory 4-quar't size porcelain jar mill loaded with l-inch size (average) flint pebbles in a weight ratio of one chitin to two pebbles. Dry ice is then put on top of the mill charge and the mill is kept open for 5 minutes to allow the CO to displace the air in the mill. The lid of the mill is then clamped on tight and the grinding carried out for 96 hours. Approximately 50% of the powdered chitin passed through a 40 micron screen.
The whole powdered chitin so produced is then applied to the 45 test rats of 45 pairs of rats used in the Prudden et al assay method described above. The percent of wound healing for the treated rats, stating the control rats as 100%, is 122%, i.e., the use of chitin results in an average 22% increase in wound healing activity.
EXAMPLES 25 Various fungi are grown on either brain-heart infusion (200 gm. calf brain, 250 gm. beef heart, 10 gm. proteose peptone, 2 gm. dextrose, 5 gm. sodium chloride and 2.5 gm. disodium phosphate) called BHI or on Sabourauds broth (40 gm. dextrose and 10 gm. bacto-peptone) called SAB. The cultures are grown in shallow layers of media contained in flasks and held stationary until good growth and extensive sporulation occurs. Prior to collection of the growth mats, the cultures are killed by placing the flasks into a closed oven under CO at 127C. for 3 hours. The flasks are then cooled in the oven for an additional 1 hour and 15 minutes. Culture broths are removed by filtration through Buchner funnels and the growth mats washed with distilled water. The mats are then frozen and lyophilized and the dry products ground in a mortar with a pestle under CO No attempt is made to purify the chitin. Twelve pairs of rats are used for each test. Some inflammation is observed on all treated wounds and infection on several. The increases in wound healing obtained may be all the more significant in view of those adverse factors.
Wound Healing lmprove Example Fungus Medium (Control l) ment 2 Mucor spinosus SAB 136 36 3 Aspergillus niger BF 1 l8 l8 4 Penicillium Bl-ll 146 46 5 Cryptacoccus BHl 128 28 EXAMPLE 6 100 grams of dried fungus material (obtained from Penicillium fungus of Example 4, cultured on a BHl medium, sterilized by boiling the fungus with the medium and then filtering, washing with distilled water and drying the fungus material) is defatted by extracting the solvent-soluble fatty materials with 1,000 ml. chloroform at room temperature. The chloroform is removed by filtering and then drying at reduced pressure in a vacuum desiccator.
The defatted fungus material is treated with 2,000 ml. 1.0 NNaOl-l solution for 18 hours at room temperature, The material is then acidified with HCl. Thereafter the material is dialyzed in distilled water until the wash water is free from chlorine ions. This procedure is repeated until a substantially purified material is obtained. The material is dried in vacuum below 50C and is a gray, friable mass.
The dried material is ground in a laboratory mortar and screened through a 400 mesh standard screen. When the screened material is applied to 20 test rats of 20 pairs of rats there is obtained an average of about 25% increase in the wound healing of the treated rats over the untreated control rats.
EXAMPLE 7 Lobster shell chitin is purified by first slurrying it in 10% aqueous NaOH for 5 minutes at 80C, then it is washed, drained and slurried in 10% HCl for 5 minutes at 80C, drained, slurried in water, the pH of the water adjusted to 6 with dilute aqueous NaOH, and finally drained and dried.
The dried chitin material is pulverized to a fineness of about 40 microns. The material shows an average 25% increase in the wound healing over the untreated control rats.
Although the present invention has been described in conjunction with preferred embodiments, it is to be understood that modifications and variations may be re sorted to without departing from the spirit and scope thereof, as those skilled in the art will readily understand.
What is claimed is:
l. A process for facilitating healing of a wound in a mammal which comprises administering to said mammal a therapeutically effective wound healing amount of a material cmprising an N-acetylated partially depolymerized chitin.
2. A process according to claim 1 wherein said therapeutically effective dose is administered by injection.
3. A process according to claim 1 wherein said N- acetylated partially depolymerized chitin is a chitoboise.
4. A process according to claim 1 wherein said N- acetylated partially depolymerized chitin is a chitobiose.
5. A process for facilitating healing of a surgical wound in a mammal afflicted with said wound which comprises orally administering to said mammal a therapeutically effective wound healing amount of a material comprising an N-acetylated partially depolymerized chitin.
6. A process according to claim 5, wherein said therapeutically effective dose is topically administered at the site of said wound.
7. A process according to claim 6, wherein said therapeutically effective dose is administered by injection.
8. A process for facilitating healing of an open ulcer wound in a mammal which comprises topically administering to said mammal a therapeutically effective wound healing amount of a material comprising an N- acetylated partially depolymerized chitin.
9. The process according to claim 8, wherein said N- acetylated partially depolymerized chitin is a chitoboise.
10. A process according to claim 1 wherein said therapeutically effective dose is orally administered.
11. The process according to claim 1 which comprises parenterally administering said N-acetylated partially depolymerized chitin.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2040879 *||Jun 21, 1934||May 19, 1936||Du Pont||Substantially undegraded deacetylated chitin and process for producing the same|
|US2795579 *||Oct 9, 1953||Jun 11, 1957||Warner Lambert Pharmaceutical||Process for purification of chitosan by means of the salicylic acid salt thereof|
|US3232836 *||Aug 24, 1959||Feb 1, 1966||Pfizer & Co C||Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine|
|US3257275 *||Feb 7, 1962||Jun 21, 1966||Weisberg Mark||Chitosan containing antacid composition and method of using same|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4074366 *||Jul 22, 1976||Feb 21, 1978||American Cyanamid Company||Poly(N-acetyl-D-glucosamine) products|
|US4074713 *||Jul 22, 1976||Feb 21, 1978||American Cyanamid Company||Poly(N-acetyl-D-glucosamine) products|
|US4086335 *||Oct 29, 1975||Apr 25, 1978||Bruscato Frank N||Pharmaceutical tablets containing chitin as a disintegrant|
|US4486416 *||Mar 2, 1981||Dec 4, 1984||Soll David B||Protection of human and animal cells subject to exposure to trauma|
|US4572906 *||Oct 2, 1984||Feb 25, 1986||Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government||Chitosan based wound dressing materials|
|US4605623 *||Aug 15, 1983||Aug 12, 1986||Malette William Graham||Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture|
|US4613502 *||Dec 6, 1984||Sep 23, 1986||Ceskoslovenska Akademie Ved||Proteolytic, dry biopolymeric composition for treatment of wounds, and method of using same|
|US4645757 *||Jan 30, 1984||Feb 24, 1987||Landstingens Inkopscentral Lic Ekonomisk Forening||Agent for preventing or treating infections in human beings and animals|
|US4873092 *||May 21, 1987||Oct 10, 1989||Murata Kikai Kabushiki Kaisha||Slow-releasing preparation|
|US4920158 *||Aug 22, 1988||Apr 24, 1990||Medipro Sciences Limited||Hydrogel-forming wound dressing or skin coating material|
|US4931271 *||Apr 16, 1987||Jun 5, 1990||Wella Aktiengesellschaft||Cosmetic compostions based upon N-hydroxybutyl-chitosans, N-hydroxybutyl-chitosans as well as processes for the production thereof|
|US4931551 *||Jul 5, 1988||Jun 5, 1990||University Of Delaware||Dispersions of chitin and product therefrom|
|US4971956 *||Jun 7, 1989||Nov 20, 1990||Ihara Chemical Industry Co., Ltd.||Immunopotentiating agents and method|
|US5013769 *||Feb 6, 1990||May 7, 1991||Medipro Sciences Limited||Method of making a hydrogel-forming wound dressing or skin coating material|
|US5021207 *||Dec 19, 1988||Jun 4, 1991||E. I. Du Pont De Nemours And Company||High strength fibers from chitin derivatives|
|US5605938 *||May 31, 1991||Feb 25, 1997||Gliatech, Inc.||Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate|
|US5705177 *||May 29, 1992||Jan 6, 1998||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US5705178 *||Dec 8, 1993||Jan 6, 1998||Gliatech, Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US5733884 *||Nov 7, 1995||Mar 31, 1998||Nestec Ltd.||Enteral formulation designed for optimized wound healing|
|US5994325 *||Jun 6, 1995||Nov 30, 1999||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6020326 *||Jun 6, 1995||Feb 1, 2000||Gliatech Inc.||Method for inhibition of bone growth by anionic polymers|
|US6083930 *||Jun 6, 1995||Jul 4, 2000||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6117851 *||Dec 12, 1997||Sep 12, 2000||Lescarden Inc.||Treatment of osteoarthritis by administering poly-N-acetyl-D-glucosamine|
|US6127348 *||Sep 1, 1999||Oct 3, 2000||Gliatech, Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6693188||Aug 8, 2001||Feb 17, 2004||Cargill Incorporated||N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine|
|US7413881||Jun 15, 2005||Aug 19, 2008||Cargill, Incorporated||Chitosan and method of preparing chitosan|
|US7488812||Apr 2, 2003||Feb 10, 2009||Cargill, Incorporated||Chitosan production|
|US7816514||Oct 13, 2003||Oct 19, 2010||Cargill, Incorporated||Glucosamine and method of making glucosamine from microbial biomass|
|US7923437||Mar 31, 2006||Apr 12, 2011||Cargill, Incorporated||Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same|
|US8034925||Mar 18, 2010||Oct 11, 2011||Cargill, Incorporated||Glucosamine and method of making glucosamine from microbial biomass|
|US8222232||Mar 31, 2006||Jul 17, 2012||Cargill, Incorporated||Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass|
|US8263763||Jun 20, 2005||Sep 11, 2012||Taiwan Hopax Chemicals Manufacturing Company, Ltd.||Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound|
|US8389498||Mar 26, 2010||Mar 5, 2013||Taiwan Textile Research Institute||Spinning solution and method for manufacturing biomaterial fibers|
|US8486033||Apr 16, 2010||Jul 16, 2013||Marine Polymer Technologies, Inc.||Application of polymeric materials to screens to facilitate hemostasis and wound healing|
|US8517979||Dec 21, 2009||Aug 27, 2013||Abbott Laboratories||Carriers for hemostatic tract treatment|
|US8715719||Jun 16, 2010||May 6, 2014||Abbott Vascular, Inc.||Stable chitosan hemostatic implant and methods of manufacture|
|US8992453 *||Mar 8, 2012||Mar 31, 2015||Marine Polymer Technologies, Inc.||Vascular access preservation in hemodialysis patients|
|US9533076||Aug 26, 2013||Jan 3, 2017||Abbott Laboratories||Carriers for hemostatic tract treatment|
|US9610378||Dec 28, 2012||Apr 4, 2017||Cg Bio Co., Ltd.||Antimicrobial wound-covering material and method for manufacturing same|
|US20030148998 *||Dec 19, 2002||Aug 7, 2003||Cargill, Incorporated||Glucosamine and method of making glucosamine from microbial biomass|
|US20040077055 *||Oct 13, 2003||Apr 22, 2004||Cargill, Incorporated||Glucosamine and method of making glucosamine from microbial biomass|
|US20050215774 *||Apr 2, 2003||Sep 29, 2005||Trinkle Jamea R||Chitosan production|
|US20050245482 *||Jun 15, 2005||Nov 3, 2005||Weiyu Fan||Chitosan and method of preparing chitosan|
|US20050283004 *||Jun 18, 2004||Dec 22, 2005||Hopax Chemicals Manufacturing Co., Ltd.||Alkylsulfonated polyaminosaccharides|
|US20060003965 *||Oct 31, 2003||Jan 5, 2006||Fosdick Lawrence D||N-acetyl-d-glucosamine (nag) supplemented food products and beverages|
|US20060025583 *||Jun 20, 2005||Feb 2, 2006||Taiwan Hopax Chemicals Manufacturing Company, Ltd.||Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound|
|US20060058263 *||Oct 31, 2003||Mar 16, 2006||Rogers Brent D||Heat pasturized liquids containing glucosamine|
|US20060172392 *||Mar 31, 2006||Aug 3, 2006||Cargill, Incorporated||Water soluble beta-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same|
|US20060178344 *||Mar 31, 2006||Aug 10, 2006||Cargill, Incorporated||Glucosamine and N-acetylglucosamine and methods of making the same fungal biomass|
|US20060246114 *||Oct 31, 2003||Nov 2, 2006||Rogers Brent D||Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine|
|US20090099347 *||Dec 19, 2008||Apr 16, 2009||Cargill, Incorporated||Chitosan production|
|US20100003292 *||Nov 20, 2007||Jan 7, 2010||Sandrine Gautier||Fine-granulometry fungal extract chitine-glucane|
|US20100228185 *||Dec 21, 2009||Sep 9, 2010||Abbott Laboratories||Carriers for hemostatic tract treatment|
|US20110015586 *||Apr 16, 2010||Jan 20, 2011||Orgill Dennis P||Application of polymeric materials to screens to facilitate hemostasis and wound healing|
|US20110237539 *||Mar 26, 2010||Sep 29, 2011||Taiwan Textile Research Institute||Spinning Solution and Method for Manufacturing Biomaterial Fibers|
|US20120220958 *||Mar 8, 2012||Aug 30, 2012||Marine Polymer Technologies, Inc.||Vascular access preservation in hemodialysis patients|
|DE3321446A1 *||Jun 14, 1983||May 10, 1984||William Graham Malette||Verwendung von chitosan oder polygluklosamin zur erzielung einer haemostase, zur inhibierung der fibroplasie und zur foerderung der geweberegeneration einer wunde|
|EP0183556A2 *||Nov 28, 1985||Jun 4, 1986||IHARA CHEMICAL INDUSTRY Co., Ltd.||Use of chitin- or chitosan-oligomers for the manufacture of a immunopotentiating agent for enhancing the immune response against bacterial and fungal infections and against the growth of tumours|
|EP0183556A3 *||Nov 28, 1985||Sep 16, 1987||Ihara Chemical Industry Co., Ltd.||Immunopotentiating agents and method|
|EP0692253A1 *||Feb 3, 1994||Jan 17, 1996||Nippon Soda Co., Ltd.||Prophylatic for domestic animal mastitis|
|EP0692253A4 *||Feb 3, 1994||Jun 3, 1998||Nippon Soda Co||Prophylatic for domestic animal mastitis|
|EP1607406A1||Jun 17, 2005||Dec 21, 2005||Taiwan Hopax Chems. Mfg. Co., Ltd||Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound|
|WO1986005789A1 *||Mar 25, 1986||Oct 9, 1986||Biocarb Ab||Carbohydrate derivatives and compositions thereof for therapeutic or diagnostic use, and methods for their use|
|WO2008061999A1 *||Nov 20, 2007||May 29, 2008||Kitozyme Sa||Fine-granulometry fungal extract chitine-glucane|
|WO2013109004A1||Dec 28, 2012||Jul 25, 2013||Cg Bio Co., Ltd.||Antimicrobial wound-covering material and method for manufacturing same|
|U.S. Classification||514/55, 424/447, 424/538, 514/925|
|International Classification||A61K31/715, C08B37/08|
|Cooperative Classification||A61K31/715, C08B37/003, Y10S514/925|
|European Classification||C08B37/00M3B2, A61K31/715|
|Apr 1, 1983||AS||Assignment|
Owner name: LESCARDEN INC.,
Free format text: CHANGE OF NAME;ASSIGNOR:LESCARDEN LTD.;REEL/FRAME:004123/0510
Effective date: 19830105